SiBone (NASDAQ:SIBN) Stock: Insider Jeffrey Dunn Sells 20,000 Shares

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 20,000 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $20.89, for a total transaction of $417,800.00. Following the completion of the transaction, the director owned 16,057 shares of the company’s stock, valued at approximately $335,430.73. This represents a 55.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

SiBone Price Performance

NASDAQ:SIBN opened at $24.27 on Friday. The company has a 50-day moving average of $19.71 and a 200-day moving average of $16.56. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -78.29 and a beta of 0.64. SiBone has a 52 week low of $11.48 and a 52 week high of $25.92. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.55 and a current ratio of 7.58.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. The business had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. As a group, equities research analysts anticipate that SiBone will post -0.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SIBN. TD Cowen lifted their price objective on SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a report on Tuesday. Citigroup reiterated a “market outperform” rating on shares of SiBone in a research note on Tuesday. Needham & Company LLC dropped their target price on SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a report on Tuesday. UBS Group raised their target price on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Institutional Investors Weigh In On SiBone

Several large investors have recently made changes to their positions in the company. First Light Asset Management LLC increased its holdings in shares of SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after buying an additional 2,774,795 shares in the last quarter. Granahan Investment Management LLC raised its stake in shares of SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after acquiring an additional 858,942 shares during the last quarter. Paradigm Capital Management Inc. NY boosted its holdings in shares of SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after acquiring an additional 598,300 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of SiBone by 101.6% in the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock worth $5,969,000 after acquiring an additional 238,219 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after acquiring an additional 182,465 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.